Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect.

Stader, F.; Khoo, S.; Stoeckle, M.; Back, D.; Hirsch, H.H.; Battegay, M.; Marzolini, C.

doi:10.1093/jac/dkaa253

Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect.

Détails

Télécharger: Stader.pdf (134.24 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY 4.0

ID Serval

serval:BIB_43B047B70CB0

Type

Article: article d'un périodique ou d'un magazine.

Collection

Publications

Institution

UNIL/CHUV

Titre

Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect.

Périodique

The Journal of antimicrobial chemotherapy

Auteur⸱e⸱s

Stader F., Khoo S., Stoeckle M., Back D., Hirsch H.H., Battegay M., Marzolini C.

ISSN

1460-2091 (Electronic)

ISSN-L

0305-7453

Statut éditorial

Publié

Date de publication

01/10/2020

Peer-reviewed

Oui

Volume

75

Numéro

10

Pages

3084-3086

Langue

anglais

Notes

Publication types: Letter ; Research Support, Non-U.S. Gov't
Publication Status: ppublish

Mots-clé

Adult, Aged, Aged, 80 and over, Betacoronavirus, COVID-19, Coronavirus Infections/drug therapy, Coronavirus Infections/metabolism, Cytochrome P-450 CYP3A Inhibitors/administration & dosage, Cytochrome P-450 CYP3A Inhibitors/metabolism, Drug Interactions/physiology, Drug Therapy, Combination, Female, Humans, Lopinavir/administration & dosage, Lopinavir/metabolism, Male, Middle Aged, Pandemics, Pneumonia, Viral/drug therapy, Pneumonia, Viral/metabolism, Ritonavir/administration & dosage, Ritonavir/metabolism, SARS-CoV-2, Time Factors, Withholding Treatment/trends, Young Adult

URN

urn:nbn:ch:serval-BIB_43B047B70CB05

OAI-PMH

oai:serval.unil.ch:BIB_43B047B70CB0

DOI

10.1093/jac/dkaa253

Pubmed

32556272

Web of science

000584502800057

Open Access

Oui